Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK plus cohort updated biomarker analyses

被引：1

作者：

Gadgeel, S. M. ^{[1
]}

Yan, M. ^{[2
]}

Paul, S. M. ^{[3
]}

Mathisen, M. ^{[4
]}

Mocci, S. ^{[3
]}

Assaf, Z. J. ^{[3
]}

Patel, R. ^{[3
]}

Sokol, E. S. ^{[5
]}

Mok, T. ^{[6
]}

Peters, S. ^{[7
]}

Paz-Ares, L. ^{[8
]}

Dziadziuszko, R. ^{[9
]}

机构：

[1] Henry Ford Hosp, Henry Ford Canc Inst, Dept Internal Med, Detroit, MI 48202 USA

[2] F Hoffmann La Roche & Cie AG, Biometr, Mississauga, ON, Canada

[3] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA

[4] Genentech Inc, Prod Dev Oncol Clin Sci, San Francisco, CA 94080 USA

[5] Fdn Med Inc, Canc Genom, Cambridge, MA USA

[6] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong, Peoples R China

[7] Ctr Hosp Univ Vaudois CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland

[8] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain

[9] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1615

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1301P

引用

页码：S841 / S841

页数：1

共 50 条

[1] Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
Mok, T.
Dziadziuszko, R.
Peters, S.
He, X.
Riehl, T.
Schleifman, E.
Paul, S.
Mocci, S.
Shames, D.
Mathisen, M.
Gadgeel, S.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1975 - S1976
[2] Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naive NSCLC: Initial results from the ALK plus cohort
Gadgeel, S. M.
Mok, T. S. K.
Peters, S.
Alexander, J. A. A.
Leighl, N. B.
Sriuranpong, V.
Perol, M.
De Castro, G., Jr.
Nadal, E.
De Marinis, F.
Han, J-Y.
Yan, M.
Riehl, T.
Schleifman, E.
Paul, S. M.
Mocci, S.
Shames, D.
Mathisen, M. S.
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2019, 30 : 918 - 918
[3] Higher Dose Alectinib for Advanced RET plus NSCLC: Results from the RET plus Cohort of the Blood First Assay Screening Trial (BFAST)
Peled, N.
Ponce, S.
Alatorre-Alexander, J.
Kinkolykh, A.
Vicuna, B.
Mathisen, M.
Mocci, S.
Paul, S.
Schleifman, E.
Dziadziuszko, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S684 - S684
[4] Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC : Initial Results of the Phase 2 ALK-Positive Cohort
Dziadziuszko, Rafal
Mok, Tony
Peters, Solange
Han, Ji-Youn
Alatorre-Alexander, Jorge
Leighl, Natasha
Sriuranpong, Virote
Perol, Maurice
de Castro Junior, Gilberto
Nadal, Ernest
de Marinis, Filippo
Frontera, Osvaldo Aren
Tan, Daniel S. W.
Lee, Dae Ho
Kim, Hye Ryun
Yan, Mark
Riehl, Todd
Schleifman, Erica
Paul, Sarah M.
Mocci, Simonetta
Patel, Rajesh
Assaf, Zoe June
Shames, David S.
Mathisen, Michael S.
Gadgeel, Shirish M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2040 - 2050
[5] Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
Dziadziuszko, R.
Peters, S.
Gadgeel, S. M.
Mathisen, M. S.
Shagan, S. M.
Felip, E.
Morabito, A.
Cheema, P.
Cobo Dols, M.
Andric, Z.
Barrios, C. H.
Yamaguchi, M.
Dansin, E.
Danchaivijitr, P.
Johnson, M.
Novello, S.
Gandara, D. R.
Schleifman, E.
Wang, J.
Mok, T. S. K.
ANNALS OF ONCOLOGY, 2021, 32 : S950 - S951
[6] Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1 +) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)
Peters, Solange
Gadgeel, Shirish M.
Mok, Tony S. K.
Nadal, Ernest
Kilickap, Saadettin
Perol, Maurice
Cadranel, Jacques
Sugawara, Shunichi
Chiu, Chao-Hua
Moskovitz, Mor
Yu, Chong-Jen
Tanaka, Tomohiro
Nersesian, Rhea
Shagan, Sarah M.
Maclennan, Margaret
Mathisen, Michael
Prasad, Vijay N. S. Bhagawati
Archer, Venice Rosalie
Dziadziuszko, Rafal
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[7] Alectinib for treatment-naive advanced ALK plus NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Gadgeel, S. M.
Mok, T. S. K.
Peters, S.
Nadal, E.
Han, J-Y.
Alexander, J. A. Alatorre
Leighl, N.
Sriuranpong, V.
Perol, M.
Castro, G. D.
de Marinis, F.
Tan, D. S. W.
Paul, S.
Assaf, Z. J.
MacLennan, M.
Lohmann, T. O.
Slade, M.
Mathisen, M. S.
Bhagawati-Prasad, V.
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2023, 34
[8] Blood first line ready screening trial ( B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic
Mok, T. S. K.
Gadgeel, S.
Kim, E. S.
Velcheti, V.
Hu, S.
Riehl, T.
Schleifman, E.
Paul, S. M.
Mocci, S.
Shames, D. S.
Phan, S.
Yun, C.
Mathisen, M.
Kowanetz, M.
Sweere, U.
Socinski, M. A.
ANNALS OF ONCOLOGY, 2017, 28
[9] Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial
Ahn, M. -J.
Delmonte, A.
Ghosh, S.
Hochmair, M.
Yang, T. -Y.
Yang, J. C. -H.
Han, J. -Y.
Hansen, K. Holmskov
Wu, Y.
Wan, Y.
Lin, H. M.
Kretz, J.
Hupf, B.
Kurec, A. M.
Churchill, E. N.
Fram, R. J.
Cabasag, C. J.
Goriya, V.
Zhao, Y.
Gemmen, E.
Campelo, M. R. Garcia
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S200 - S200
[10] Real-World Treatment Patterns and Effectiveness in Patients with ALK plus Advanced NSCLC Treated with 1L ALK TKIs
Chen, Y.
Lin, H. M.
Wan, Y.
Yin, Y.
Wu, Y.
Hernandez, L.
Danes, C.
Churchill, E. N.
Dimou, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641

← 1 2 3 4 5 →